Janux Therapeutics reports FY2024 net loss $69M, cash $1.03B, positive JANX007 data

Janux Therapeutics, Inc.

2024-FY EPS reported -$1.28 revenue$10,588,000

Cash and short-term investments $1.03B at year-end 2024, up from $344M in 2023, largely from $402.5M December offering.
Net loss $69.0M for FY2024 ($20.2M Q4), vs $58.3M prior year; R&D spend $68.4M.
JANX007 PSMA-TRACTr Phase 1: 100% PSA50, 63% PSA90, 50% ORR (4/8), well-tolerated safety; data cutoff Nov 15, 2024.
JANX008 EGFR TRACTr Phase 1 enrollment ongoing; data update and R&D Day planned for 2025.
Zachariah McIver promoted to Chief Medical Officer; he previously served as Amgen's Executive Medical Director.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.